IL-23s: Psoriasis therapy overview

(1:51)

Selecting from IL-23s

(3:35)

Discussing Risankizumb, Differences in IL-23 Inhibitor Epitopes with Christopher Bunick, MD, PhD

(9:52)

Efficacy of IL-23 Inhibitors in Plaque Psoriasis

(7:16)

Safety and Efficacy of IL-23 Inhibitors in Plaque Psoriasis

(4:12)

Use of IL-23 Inhibitors to Treat Plaque Psoriasis

(5:11)

IL23 \u0026 IL12/23 Inhibitors: An Overview

(2:34)

WCH23: IL-17 vs IL-23 Blockers – Why and When?

(3:24)

First Baptist Church Decatur IL Livestream 11-12-23

(11)

Treating Plaque Psoriasis: IL-17 and IL-23 Inhibitors

(5:19)

Evolving Therapeutic Strategies for Psoriatic Diseases: Not all IL-23s are Created Similar

(1:29:16)

Targeting IL-12/IL-23 in Crohn’s Disease

(4:17)

lxekizumab Reduces key IL-17 and IL-23 Pathway Genes More Rapidly than Guselkumab | Lam Tsoi, PhD

(7:49)

Exploring New Targets in the IL-23/IL-17 Pathway for Psoriasis

(26:56)

PsA Perspectives - IL-23: Dr. Eric Ruderman

(3:41)

IL-17 and IL-23 inhibitors in the treatment of psoriatic arthritis

(1:43)

Benjamin Lockshin, MD - If changing from IL-17 to an IL-23, when can you can initiate a new drug?

(38)

The role of Il-23 in Autoimmunity

(2:47)

IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis

(6:14)

IL-17 inhibitors and IL-23 inhibitors in psoriasis

(2:34)